Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
monoclonal antibody
|
| gptkbp:activeDuring |
gptkb:guselkumab
|
| gptkbp:administrativeDivision |
every 8 weeks after initial dose
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:barrelLength |
high affinity for IL-23
|
| gptkbp:chemicalFormula |
IgG1 kappa monoclonal antibody
|
| gptkbp:clinicalTrials |
gptkb:DISCOVER-1
gptkb:DISCOVER-2 Phase 3 VOYAGE 1 VOYAGE 2 chronic inflammatory conditions |
| gptkbp:contraindication |
active infections
thrombocytopenia neutropenia serious infections malignancies hypersensitivity_to_guselkumab |
| gptkbp:date |
2017
|
| gptkbp:developedBy |
gptkb:Janssen_Pharmaceuticals
|
| gptkbp:dosageForm |
solution for injection
|
| gptkbp:drugInterdiction |
linear pharmacokinetics
inhibits IL-23 mediated signaling |
| gptkbp:endOfLife |
approximately 15 days
|
| gptkbp:firstAppearance |
2017
|
| gptkbp:hasPopulation |
adults
children over 6 years old |
| https://www.w3.org/2000/01/rdf-schema#label |
guselkumab
|
| gptkbp:impact |
improve quality of life
reduce symptoms long-term treatment clear or almost clear skin |
| gptkbp:issuedBy |
subcutaneous injection
|
| gptkbp:mandates |
active psoriatic arthritis
moderate to severe plaque psoriasis |
| gptkbp:manufacturer |
gptkb:Janssen_Biotech
|
| gptkbp:marketedAs |
gptkb:Tremfya
|
| gptkbp:patentStatus |
patented
|
| gptkbp:reproduction |
low immunogenic potential
|
| gptkbp:researchAreas |
rheumatology
dermatology immunology |
| gptkbp:route |
subcutaneous
|
| gptkbp:safetyFeatures |
generally well tolerated
|
| gptkbp:sideEffect |
headache
injection site reactions upper respiratory infections |
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
IL-23
|
| gptkbp:triggerType |
inhibits IL-23 pathway
|
| gptkbp:usedFor |
psoriasis
psoriatic arthritis |